StockNews.AI
TRML
StockNews.AI
92 days

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

1. Tourmaline will present Phase 2 trial results on May 20, 2025. 2. Pacibekitug targets chronic kidney disease and inflammatory diseases. 3. Dr. Deepak L. Bhatt will join the conference to discuss findings. 4. Pacibekitug exhibits best-in-class potential with a long half-life. 5. Company explores expanding indications for pacibekitug beyond current trials.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical trial results typically boost stock prices for biotech firms. Historical cases show spikes in share price after successful trial announcements.

How important is it?

The conference call outcomes could drive stock movements, contingent on trial results. High public interest and the potential market of pacibekitug increase its importance.

Why Short Term?

The upcoming Phase 2 results will likely prompt immediate market reactions. Past biotech announcements have shown rapid impacts within days of such news.

Related Companies

REGNAMGNABBV
May 19, 2025 16:05 ET  | Source: Tourmaline Bio, Inc. NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, will host a conference call and webcast on Tuesday, May 20, 2025 beginning at 8:30 a.m. ET to present topline results from the Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Members of Tourmaline management will be joined by Dr. Deepak L. Bhatt, Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai in New York. Dr. Bhatt also serves as the Chair of Tourmaline’s Cardiovascular Scientific Advisory Board (for which he is compensated). To register for this event, please click here or visit the “Events and Presentations” section of Tourmaline’s website. A replay will be available on Tourmaline’s website following the event. About Tourmaline Bio:Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug. For more information, please visit https://www.tourmalinebio.com or follow us on LinkedIn or X. About Pacibekitug:Pacibekitug is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. Excluding ongoing trials, pacibekitug was previously studied in approximately 450 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is currently developing pacibekitug in atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED) as its first two indications, with plans to expand into abdominal aortic aneurysm (AAA) and additional diseases in the future. Media Contact:Scient PRSarah MishekSMishek@ScientPR.com Investor Contact:Meru AdvisorsLee M. Sternlstern@meruadvisors.com

Related News